Volume 16 Supplement 1
Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications
Meeting abstracts
Edited by Johannes-Peter Stasch, John Burnett, Harald Schmidt, Michaela Kuhn and Franz Hofmann
Publication of this supplement has been fully funded by FEBGLA e.V. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.
7th International Conference on cGMP Generators, Effectors and Therapeutic Implications. Go to conference site.
Trier, Germany19-21 June 2015
Page 1 of 3
-
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A1
-
The clinical development of sGC modulators, riociguat and vericiguat
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A2 -
MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A3 -
A soluble guanylate cyclase activator protects from diabetic nephropathy beyond standard of care in the ZSF1 rat
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A4 -
The discovery and characterization of novel soluble guanylate cyclase stimulators
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A5 -
Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A6 -
Natriuretic peptides and cGMP in metabolic disease
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A7 -
Soluble guanylyl cyclase regulates skeletal muscle fiber type plasticity, fatigue resistance and whole body insulin resistance
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A8 -
Gene therapy approaches to restore retinal cGMP channel function
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A9 -
NO/GMP as mediators of estrogen effects in bone
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A10 -
Using PDE5 inhibitors for the prevention and treatment of colorectal cancer
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A11 -
cGMP and cardiac hypertrophy
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A12 -
Cyclic GMP/cGMP-dependent protein kinase type I signaling and cysteine-rich LIM-only protein 4 in AngII/AT1R-induced heart hypertrophy and fibrosis
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A13 -
Roles of 8-nitro-cGMP in autophagy regulation
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A14 -
Structural basis of cyclic nucleotide selectivity in cGMP dependent protein kinase II
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A15 -
cGMP and cAMP pathways rearrange ARHGAP17 and ARHGEF6 protein complexes to control Rac1 in platelets
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A16 -
New insights into leveraging PKG signalling to treat diseased hearts
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A17 -
Targeting cyclic nucleotides in CNS drug discovery: a translational approach into cognition enhancement
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A18 -
Inhibition of cGMP-metabolizing PDEs as target for cognitive enhancement
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A19 -
Ultrasensitive signal detection by a guanylyl cyclase chemoreceptor
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A20 -
Mechanism and protective properties of S-nitrosation by nitric oxide in cardiac mitochondria
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A21 -
Novel roles of cardiac natriuretic peptides in renal compensatory hypertrophy
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A22 -
Antifibrotic function of cGKI in the kidney
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A23 -
Mixed linage kinase 3 functions as a cGMP-dependent protein kinase I alpha substrate and regulates blood pressure and cardiac remodeling in vivo
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A24 -
The cyclic nucleotide 3’,5’-cIMP produced by sGC is a second messenger in the vascular wall
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A25 -
sGC redox regulation and asthma
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A26 -
Pivotal vascular homeostatic role for endothelium-derived C-type natriuretic peptide (CNP)
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A27 -
Implication of C-type natriuretic peptide derived from vascular endothelial cells on blood pressure regulation
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A28 -
Receptor guanylyl cyclase-G is a sensory protein activated by cool temperatures and predator odor 2,4,5-trimethylthiazoline
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A29 -
Dephosphorylation of juxtamembrane serines and threonines of the NPR2 guanylyl cyclase regulates oocyte meiotic resumption
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A30 -
Hormone suppression silencing GUCY2C is required for colorectal cancer
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A31 -
Computational exploration of the binding mode of the heme-dependent activator YC-1 into the active catalytic site of soluble guanylate cyclase
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A32 -
Investigation of the role of multidrug resistance proteins (MRPs) in vascular homeostasis
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A33 -
Construction of novel cGMP FRET-sensors based on PKG from Plasmodium falciparum
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A34 -
Anemia of cGKI deficient mice is caused by intestinal bleeding
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A35 -
A case of chaos? NO causes arrhythmic motor pattern via interstitial cells of Cajal in the murine colon
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A36 -
Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated with Reduced NT-proANP, Increased Stroke and Higher Diastolic Blood Pressure
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A37 -
Inhaled Nitric Oxide: an sGC-dependent IOP lowering agent
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A38 -
A systems biology approach to cGMP suggests a prominent role for sGC in stroke: Validation by mechanism-based activation of apo-sGC in non-steal dosing coveys neuroprotection and increased survival
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A39 -
The predator odor 2,4,5-trimethylthiazoline binds and activates receptor guanylyl cyclase-G to elicit innate defensive responses
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A40 -
C-type natriuretic peptide prevents activation of perivascular mast cells and inflammation in the postischemic microvasculature
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A41 -
Nitrosopersulfide (SSNO-) targets soluble guanylyl cyclase and induces vasodilation in vivo
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A42 -
Investigating the impact of a mutation in PDE5A on myocardial infarction
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A43 -
Catalytically active guanylyl cyclase-B requires glycosylation and mutations that inhibit this process cause dwarfism
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A44 -
Zebrafish as model organism for cNMP research
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A45 -
Arterial stiffness and collagen expression in mice lacking NO-sensitive guanylyl cyclase
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A46 -
Mutation of a conserved lysine in the kinase homology domain reduces the natriuretic peptide-dependent activity and phosphorylation of guanylyl cyclase-A
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A47 -
Design and directed evolution of genetically encoded cGMP sensors
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A48 -
A CNP-cGMP-cGKI-MAPK pathway promotes melanoma growth in vitro and in vivo in mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A49 -
Cyclic GMP signaling and mitochondrial BK channels in cardioprotection against ischemia/reperfusion injury
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A50
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 2.8
5-year Journal Impact Factor: 2.8
Source Normalized Impact per Paper (SNIP): 0.774
SCImago Journal Rank (SJR): 0.710
Speed 2023
Submission to first editorial decision (median days): 25
Submission to acceptance (median days): 178
Usage 2023
Downloads: 790,731
Altmetric mentions: 400
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication